1. Home
  2. OVLY vs CHRS Comparison

OVLY vs CHRS Comparison

Compare OVLY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oak Valley Bancorp (CA)

OVLY

Oak Valley Bancorp (CA)

N/A

Current Price

$27.75

Market Cap

219.0M

Sector

Finance

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.29

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OVLY
CHRS
Founded
1990
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.0M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
OVLY
CHRS
Price
$27.75
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.51
AVG Volume (30 Days)
8.4K
1.1M
Earning Date
01-23-2026
11-06-2025
Dividend Yield
2.13%
N/A
EPS Growth
N/A
N/A
EPS
2.84
1.34
Revenue
$79,783,000.00
$277,728,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$67.29
P/E Ratio
$9.74
$0.96
Revenue Growth
2.98
152.07
52 Week Low
$22.70
$0.71
52 Week High
$32.24
$1.89

Technical Indicators

Market Signals
Indicator
OVLY
CHRS
Relative Strength Index (RSI) 52.73 48.14
Support Level $27.66 $1.18
Resistance Level $28.25 $1.35
Average True Range (ATR) 0.45 0.09
MACD -0.04 0.02
Stochastic Oscillator 68.28 67.80

Price Performance

Historical Comparison
OVLY
CHRS

About OVLY Oak Valley Bancorp (CA)

Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: